Glenn Wilkins - Monday, July 6, 2020 BELLUS Health Inc. 10:30 AM EST - BELLUS Health Inc. : Announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough. BELLUS Health Inc. shares T.BLU are trading down $12.70 at $3.68.